Susquehanna Fundamental Investments LLC Acquires 54,439 Shares of Qiagen (NYSE:QGEN)

Susquehanna Fundamental Investments LLC boosted its holdings in Qiagen (NYSE:QGEN) by 235.5% in the second quarter, HoldingsChannel reports. The firm owned 77,557 shares of the company’s stock after purchasing an additional 54,439 shares during the period. Susquehanna Fundamental Investments LLC’s holdings in Qiagen were worth $3,187,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in QGEN. PNC Financial Services Group Inc. boosted its position in shares of Qiagen by 45.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 11,903 shares of the company’s stock worth $517,000 after purchasing an additional 3,698 shares in the last quarter. US Bancorp DE grew its stake in Qiagen by 21.1% in the fourth quarter. US Bancorp DE now owns 33,661 shares of the company’s stock valued at $1,462,000 after acquiring an additional 5,859 shares during the period. TD Asset Management Inc grew its stake in Qiagen by 1.0% in the fourth quarter. TD Asset Management Inc now owns 53,531 shares of the company’s stock valued at $2,330,000 after acquiring an additional 554 shares during the period. Treasurer of the State of North Carolina increased its holdings in shares of Qiagen by 2.3% during the fourth quarter. Treasurer of the State of North Carolina now owns 105,444 shares of the company’s stock valued at $4,579,000 after acquiring an additional 2,379 shares in the last quarter. Finally, Qtron Investments LLC acquired a new position in shares of Qiagen during the fourth quarter worth approximately $258,000. 70.00% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

QGEN has been the topic of a number of recent research reports. Robert W. Baird raised their price objective on shares of Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Wolfe Research raised shares of Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price target on the stock in a research report on Thursday, June 27th. Finally, JPMorgan Chase & Co. boosted their price objective on Qiagen from $52.00 to $54.00 and gave the stock an “overweight” rating in a report on Tuesday, June 18th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $50.25.

Qiagen Stock Performance

Qiagen stock opened at $45.24 on Monday. The stock has a market cap of $10.32 billion, a P/E ratio of 30.34, a price-to-earnings-growth ratio of 3.20 and a beta of 0.39. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.46 and a current ratio of 1.77. Qiagen has a fifty-two week low of $34.74 and a fifty-two week high of $47.44. The firm’s fifty day moving average price is $45.20 and its 200-day moving average price is $43.48.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.55 EPS for the quarter, topping the consensus estimate of $0.52 by $0.03. Qiagen had a return on equity of 12.92% and a net margin of 3.75%. The firm had revenue of $496.00 million for the quarter, compared to the consensus estimate of $495.45 million. During the same quarter in the previous year, the business earned $0.53 earnings per share. The company’s quarterly revenue was down .2% on a year-over-year basis. On average, equities research analysts expect that Qiagen will post 2.15 earnings per share for the current fiscal year.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.